| Title |
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
|
|---|---|
| Published in |
Biologics in Therapy, May 2013
|
| DOI | 10.1007/s13554-013-0011-z |
| Pubmed ID | |
| Authors |
Carl-Erik Flodmark, Katarina Lilja, Heike Woehling, Kajsa Järvholm |
| Abstract |
A new treatment plan was implemented at Skåne University Hospital, on economic grounds, for children requiring recombinant human growth hormone (rhGH) treatment. This involved switching patients from treatment with originator rhGHs to treatment with a biosimilar rhGH, somatropin (Omnitrope(®)), using a Dialogue Teamwork approach. The feasibility of using this approach to implement the switch of treatment was assessed, as well as the impact of the switch on treatment efficacy and cost of therapy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 41 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 28% |
| Researcher | 4 | 9% |
| Student > Bachelor | 4 | 9% |
| Student > Doctoral Student | 4 | 9% |
| Student > Postgraduate | 3 | 7% |
| Other | 9 | 21% |
| Unknown | 7 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 23% |
| Medicine and Dentistry | 10 | 23% |
| Agricultural and Biological Sciences | 6 | 14% |
| Economics, Econometrics and Finance | 2 | 5% |
| Chemistry | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 8 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2013.
All research outputs
#18,340,012
of 22,711,645 outputs
Outputs from Biologics in Therapy
#12
of 20 outputs
Outputs of similar age
#146,136
of 195,007 outputs
Outputs of similar age from Biologics in Therapy
#1
of 2 outputs
Altmetric has tracked 22,711,645 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 20 research outputs from this source. They receive a mean Attention Score of 2.2. This one scored the same or higher as 8 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,007 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them